Johnson & Johnson (NYSE:JNJ) Shares Bought by Capital Asset Advisory Services LLC

Capital Asset Advisory Services LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 8.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,539 shares of the company’s stock after acquiring an additional 2,151 shares during the period. Capital Asset Advisory Services LLC’s holdings in Johnson & Johnson were worth $4,044,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of JNJ. Norges Bank purchased a new stake in Johnson & Johnson in the 4th quarter valued at approximately $4,071,642,000. Wellington Management Group LLP lifted its stake in Johnson & Johnson by 16.4% in the 4th quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock valued at $3,764,852,000 after buying an additional 3,391,657 shares in the last quarter. International Assets Investment Management LLC lifted its stake in Johnson & Johnson by 7,875.8% in the 4th quarter. International Assets Investment Management LLC now owns 2,090,384 shares of the company’s stock valued at $327,647,000 after buying an additional 2,064,175 shares in the last quarter. Janney Montgomery Scott LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at approximately $193,050,000. Finally, Global Assets Advisory LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter worth $170,372,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.2 %

Shares of Johnson & Johnson stock opened at $146.16 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The business has a 50-day moving average of $148.14 and a 200-day moving average of $154.07. The company has a market capitalization of $351.76 billion, a PE ratio of 9.11, a P/E/G ratio of 2.43 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. During the same quarter last year, the company posted $2.68 earnings per share. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. As a group, equities analysts forecast that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date was Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.39%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research note on Monday, June 17th. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 22nd. Bank of America reduced their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Finally, Morgan Stanley cut their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. Eight equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Hold” and a consensus price target of $174.07.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.